RPCA
PBYI icon

Running Point Capital Advisors’s Puma Biotechnology PBYI Stock Holding History

Running Point Capital Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,000
Closed -$42.3K – 194
2022
Q4 		$42.3K Hold
10,000
– – 0.03% 163
2022
Q3 		$24K Hold
10,000
– – 0.02% 177
2022
Q2 		$29K Hold
10,000
– – 0.02% 173
2022
Q1 		$29K Buy
+10,000
New +$25.9K 0.02% 173

Other funds holding PBYI

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIM
Hillsdale Investment Management Toronto, Ontario, Canada $4.39B AUM 72.96% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return

Running Point Capital Advisors's PBYI Position: Q1 2023 in Review

Running Point Capital Advisors sold out of Puma Biotechnology (PBYI) in Q1 2023, closing a stake of 10,000 shares — an estimated $42.3K sold.

Running Point Capital Advisors first reported a position in PBYI in Q1 2022 and held it in 4 quarters. The position peaked at $42.3K in Q4 2022. 77 funds tracked by Wall St. Rank hold PBYI as of Q1 2023.

  • Running Point Capital Advisors reported no remaining Puma Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Running Point Capital Advisors sold 10,000 Puma Biotechnology shares in Q1 2023, an estimated $42.3K.
  • Running Point Capital Advisors first reported a position in Puma Biotechnology in Q1 2022 and held it in 4 quarters.
  • Running Point Capital Advisors's Puma Biotechnology position peaked at $42.3K in Q4 2022.
  • 77 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2023.

Based on Running Point Capital Advisors's 13F filing for Q1 2023, filed 10 May 2023.